Mirum End Period Cash Flow from 2010 to 2024

MIRM Stock  USD 46.22  0.43  0.92%   
Mirum Pharmaceuticals End Period Cash Flow yearly trend continues to be very stable with very little volatility. End Period Cash Flow is likely to grow to about 300.6 M this year. During the period from 2010 to 2024, Mirum Pharmaceuticals End Period Cash Flow quarterly data regression pattern had sample variance of 7640.1 T and median of  51,963,000. View All Fundamentals
 
End Period Cash Flow  
First Reported
2018-09-30
Previous Quarter
233.2 M
Current Value
223.4 M
Quarterly Volatility
92.5 M
 
Covid
Check Mirum Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mirum Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 12.7 M, Discontinued Operations of 0.0 or Interest Expense of 9.4 M, as well as many indicators such as Price To Sales Ratio of 6.15, Dividend Yield of 0.0 or PTB Ratio of 5.1. Mirum financial statements analysis is a perfect complement when working with Mirum Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Mirum Pharmaceuticals Correlation against competitors.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

Latest Mirum Pharmaceuticals' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Mirum Pharmaceuticals over the last few years. It is Mirum Pharmaceuticals' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mirum Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Mirum End Period Cash Flow Regression Statistics

Arithmetic Mean97,868,953
Geometric Mean71,695,973
Coefficient Of Variation89.31
Mean Deviation66,540,338
Median51,963,000
Standard Deviation87,407,685
Sample Variance7640.1T
Range288.7M
R-Value0.74
Mean Square Error3754.9T
R-Squared0.54
Significance0
Slope14,410,800
Total Sum of Squares106961.4T

Mirum End Period Cash Flow History

2024300.6 M
2023286.3 M
2022128 M
2021131.3 M
2020142.1 M
201912 M

About Mirum Pharmaceuticals Financial Statements

Mirum Pharmaceuticals investors utilize fundamental indicators, such as End Period Cash Flow, to predict how Mirum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow286.3 M300.6 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports:
Check out the analysis of Mirum Pharmaceuticals Correlation against competitors.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
6.513
Quarterly Revenue Growth
0.894
Return On Assets
(0.09)
Return On Equity
(0.40)
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.